

Comparative Effectiveness of BNT162b2 and mRNA-1273

New England Journal of Medicine

386, 105-115

DOI: [10.1056/nejmoa2115463](https://doi.org/10.1056/nejmoa2115463)

Citation Report

#	ARTICLE	IF	CITATIONS
6	Modelling SARS-CoV-2 Binding Antibody Waning 8 Months after BNT162b2 Vaccination. <i>Vaccines</i> , 2022, 10, 285.	2.1	13
8	Immune response and adverse events after vaccination against SARS-CoV-2 in adult patients with transfusion-dependent thalassaemia. <i>British Journal of Haematology</i> , 2022, 197, 576-579.	1.2	6
9	Effectiveness and safety of SARS-CoV-2 vaccine in Inflammatory Bowel Disease patients: a systematic review, meta-analysis and meta-regression. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 1244-1264.	1.9	17
10	Neutralizing antibodies to SARS-CoV-2 Omicron variant after third mRNA vaccination in health care workers and elderly subjects. <i>European Journal of Immunology</i> , 2022, 52, 816-824.	1.6	31
11	A Simple Prognostic Score for Critical COVID-19 Derived from Patients without Comorbidities Performs Well in Unselected Patients. <i>Journal of Clinical Medicine</i> , 2022, 11, 1810.	1.0	7
12	Effectiveness of the BNT162b2 Vaccine after Recovery from Covid-19. <i>New England Journal of Medicine</i> , 2022, 386, 1221-1229.	13.9	98
13	Trajectory of IgG to SARS-CoV-2 After Vaccination With BNT162b2 or mRNA-1273 in an Employee Cohort and Comparison With Natural Infection. <i>Frontiers in Immunology</i> , 2022, 13, 850987.	2.2	35
14	Vaccine Effectiveness of 3 Versus 2 Doses of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) mRNA Vaccines in a High-Risk National Population. <i>Clinical Infectious Diseases</i> , 2022, 75, e579-e584.	2.9	17
15	Effectiveness of COVID-19 vaccines. <i>Journal of Infection</i> , 2022, 84, e118-e119.	1.7	5
16	Insights From Early Clinical Trials Assessing Response to mRNA SARS-CoV-2 Vaccination in Immunocompromised Patients. <i>Frontiers in Immunology</i> , 2022, 13, 827242.	2.2	5
17	Characterization of the significant decline in humoral immune response six months post-SARS-CoV-2 mRNA vaccination: A systematic review. <i>Journal of Medical Virology</i> , 2022, 94, 2939-2961.	2.5	89
18	Comparative 6-Month Wild-Type and Delta-Variant Antibody Levels and Surrogate Neutralization for Adults Vaccinated with BNT162b2 versus mRNA-1273. <i>Microbiology Spectrum</i> , 2022, 10, e0270221.	1.2	3
19	Waning Humoral Response after COVID-19 mRNA Vaccination in Maintenance Dialysis Patients and Recovery after a Complementary Third Dose. <i>Vaccines</i> , 2022, 10, 433.	2.1	10
20	Characteristics associated with serological COVID-19 vaccine response and durability in an older population with significant comorbidity: the Danish Nationwide ENFORCE Study. <i>Clinical Microbiology and Infection</i> , 2022, 28, 1126-1133.	2.8	30
21	Comparison of Moderna versus Pfizer-BioNTech COVID-19 vaccine outcomes: A target trial emulation study in the U.S. Veterans Affairs healthcare system. <i>EClinicalMedicine</i> , 2022, 45, 101326.	3.2	29
22	Vaccination and immunotherapies in neuroimmunological diseases. <i>Nature Reviews Neurology</i> , 2022, 18, 289-306.	4.9	27
23	Could computer models be the key to better COVID vaccines?. <i>Nature</i> , 2022, 604, 22-25.	13.7	4
24	Evasion of vaccine-induced humoral immunity by emerging sub-variants of SARS-CoV-2. <i>Future Microbiology</i> , 2022, 17, 417-424.	1.0	11

#	ARTICLE	IF	CITATIONS
25	Breakthrough Infections Following mRNA SARS-CoV-2 Vaccination in Kidney Transplant Recipients. <i>Transplantation</i> , 2022, 106, 1430-1439.	0.5	18
26	Breakthrough infections after COVID-19 vaccination: Insights, perspectives and challenges. <i>Metabolism Open</i> , 2022, 14, 100180.	1.4	41
29	Boosting Humoral Immunity from mRNA COVID-19 Vaccines in Kidney Transplant Recipients. <i>Vaccines</i> , 2022, 10, 56.	2.1	25
30	mRNA-1273 and BNT162b2 COVID-19 vaccines elicit antibodies with differences in Fc-mediated effector functions. <i>Science Translational Medicine</i> , 2022, 14, eabm2311.	5.8	100
31	SARS-CoV-2 Vaccination and Myocarditis in a Nordic Cohort Study of 23 Million Residents. <i>JAMA Cardiology</i> , 2022, 7, 600.	3.0	115
32	Vaccine effectiveness against SARS-CoV-2 infection and severe outcomes among individuals with immune-mediated inflammatory diseases tested between March 1 and Nov 22, 2021, in Ontario, Canada: a population-based analysis. <i>Lancet Rheumatology</i> , The, 2022, 4, e430-e440.	2.2	28
33	Effectiveness of mRNA-1273, BNT162b2, and JNJ-78436735 COVID-19 Vaccines Among US Military Personnel Before and During the Predominance of the Delta Variant. <i>JAMA Network Open</i> , 2022, 5, e228071.	2.8	11
34	Balancing Benefits and Harms of COVID-19 Vaccines: Lessons from the Ongoing Mass Vaccination Campaign in Lombardy, Italy. <i>Vaccines</i> , 2022, 10, 623.	2.1	2
35	Communicating the Benefits of Vaccination in Light of Potential Risks. <i>JAMA Cardiology</i> , 2022, 7, 612.	3.0	2
36	Effectiveness of a second BNT162b2 booster vaccine against hospitalization and death from COVID-19 in adults aged over 60 years. <i>Nature Medicine</i> , 2022, 28, 1486-1490.	15.2	100
37	Vaccines for COVID-19: A Systematic Review of Immunogenicity, Current Development, and Future Prospects. <i>Frontiers in Immunology</i> , 2022, 13, 843928.	2.2	25
38	How to Ask the Right Question and Find the Right Answer: Clinical Research for Transplant Nephrologists. <i>Frontiers in Immunology</i> , 2022, 13, .	2.2	1
39	Relative Vaccine Effectiveness of a Severe Acute Respiratory Syndrome Coronavirus 2 Messenger RNA Vaccine Booster Dose Against the Omicron Variant. <i>Clinical Infectious Diseases</i> , 2022, 75, 2161-2168.	2.9	35
40	First-generation oral antivirals against SARS-CoV-2. <i>Clinical Microbiology and Infection</i> , 2022, 28, 1230-1235.	2.8	21
41	Comparative analysis of COVID-19 vaccine responses and third booster dose-induced neutralizing antibodies against Delta and Omicron variants. <i>Nature Communications</i> , 2022, 13, 2476.	5.8	43
42	Seroconversion rate after primary vaccination with two doses of BNT162b2 versus mRNA-1273 in solid organ transplant recipients: a systematic review and meta-analysis. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, 1566-1575.	0.4	12
43	Protection of Messenger RNA Vaccines Against Hospitalized Coronavirus Disease 2019 in Adults Over the First Year Following Authorization in the United States. <i>Clinical Infectious Diseases</i> , 2023, 76, e460-e468.	2.9	9
44	Durability analysis of the highly effective mRNA-1273 vaccine against COVID-19. , 0, , .		1

#	ARTICLE	IF	CITATIONS
46	Heterogeneous SARS-CoV-2 humoral response after COVID-19 vaccination and/or infection in the general population. <i>Scientific Reports</i> , 2022, 12, .	1.6	8
47	Real-World Effectiveness of Global COVID-19 Vaccines Against SARS-CoV-2 Variants: A Systematic Review and Meta-Analysis. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	25
48	Messenger ribonucleic acid vaccines against infectious diseases: current concepts and future prospects. <i>Current Opinion in Immunology</i> , 2022, 77, 102214.	2.4	7
49	Temporal associations of B and T cell immunity with robust vaccine responsiveness in a 16-week interval BNT162b2 regimen. <i>Cell Reports</i> , 2022, 39, 111013.	2.9	16
51	Comparative Safety of BNT162b2 and mRNA-1273 Vaccines in a Nationwide Cohort of US Veterans. <i>JAMA Internal Medicine</i> , 2022, 182, 739.	2.6	17
52	Comparative COVID-19 Vaccine Effectiveness over Time in Veterans. <i>Open Forum Infectious Diseases</i> , 0, , .	0.4	15
53	Two Cases of Acute Myocarditis in Young Male Adults After mRNA Vaccines Against COVID-19: Similarities and Differences. <i>Medicinski Arhiv = Medical Archives = Archives De MÃ©decine</i> , 2022, 76, 215.	0.4	1
54	Comparative Effectiveness of the SARS-CoV-2 Vaccines During Delta Dominance. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
55	Durability analysis of the highly effective BNT162b2 vaccine against COVID-19. , 2022, 1, .		8
59	The Role of Cellular Immunity in the Protective Efficacy of the SARS-CoV-2 Vaccines. <i>Vaccines</i> , 2022, 10, 1103.	2.1	11
60	Comparative effectiveness of ChAdOx1 versus BNT162b2 covid-19 vaccines in health and social care workers in England: cohort study using OpenSAFELY. <i>BMJ, The</i> , 0, , e068946.	3.0	15
63	COVID-19 mRNA vaccine effectiveness against hospitalisation and death in veterans according to frailty status during the SARS-CoV-2 delta (B.1.617.2) variant surge in the USA: a retrospective cohort study. <i>The Lancet Healthy Longevity</i> , 2022, 3, e589-e598.	2.0	19
64	Immunogenicity to COVID-19 mRNA vaccine third dose in people living with HIV. <i>Nature Communications</i> , 2022, 13, .	5.8	62
65	Grand challenges in oral health and nutrition: We are what we eat. <i>Frontiers in Oral Health</i> , 0, 3, .	1.2	1
66	SARS-CoV-2 prefusion spike protein stabilized by six rather than two prolines is more potent for inducing antibodies that neutralize viral variants of concern. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, .	3.3	28
69	Humoral and cellular response of COVID-19 vaccine among solid organ transplant recipients: A systematic review and meta-analysis. <i>Transplant Infectious Disease</i> , 2022, 24, .	0.7	17
70	Efficacy, immunogenicity and safety of COVID-19 vaccines in older adults: a systematic review and meta-analysis. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	15
71	Comparison of antibody response durability of mRNA-1273, BNT162b2, and Ad26.COV2.S SARS-CoV-2 vaccines in healthcare workers. <i>International Journal of Infectious Diseases</i> , 2022, 123, 183-191.	1.5	8

#	ARTICLE	IF	CITATIONS
73	Antibody and Tâ€cell responses by ultraâ€deep Tâ€cell receptor immunosequencing after COVID-19 vaccination in patients with plasma cell dyscrasias. <i>British Journal of Haematology</i> , 2022, 199, 520-528.	1.2	4
74	Hybrid and vaccineâ€induced immunity against SARS-CoV-2 in MS patients on different diseaseâ€modifying therapies. <i>Annals of Clinical and Translational Neurology</i> , 2022, 9, 1643-1659.	1.7	9
75	Response to COVID-19 vaccine is reduced in patients with inflammatory bowel disease, but improved with additional dose. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2023, 38, 44-51.	1.4	6
76	Immunogenicity of two doses of BNT162b2 and mRNA-1273 vaccines for solid cancer patients on treatment with or without a previous SARS-CoV-2 infection. <i>International Journal of Cancer</i> , 2023, 152, 661-671.	2.3	3
78	Breakthrough SARS-CoV-2 infection outcomes in vaccinated patients with chronic liver disease and cirrhosis: A National COVID Cohort Collaborative study. <i>Hepatology</i> , 2023, 77, 834-850.	3.6	7
79	Associations of Immunogenicity and Reactogenicity After Severe Acute Respiratory Syndrome Coronavirus 2 mRNA-1273 Vaccine in the COVE and TeenCOVE Trials. <i>Clinical Infectious Diseases</i> , 2023, 76, 271-280.	2.9	3
80	Real-world comparative effectiveness of mRNA-1273 and BNT162b2 vaccines among immunocompromised adults identified in administrative claims data in the United States. <i>Vaccine</i> , 2022, 40, 6730-6739.	1.7	7
81	Evaluating risk factors associated with COVID-19 infections among vaccinated people early in the U.S. vaccination campaign: an observational study of five states, Januaryâ€March 2021. <i>BMC Infectious Diseases</i> , 2022, 22, .	1.3	0
82	Incidence of Severe COVID-19 Illness Following Vaccination and Booster With BNT162b2, mRNA-1273, and Ad26.COV2.S Vaccines. <i>JAMA - Journal of the American Medical Association</i> , 2022, 328, 1427.	3.8	36
83	Benefits and Risks Associated With Continuation of Antiâ€Tumor Necrosis Factor After 24 Weeks of Pregnancy in Women With Inflammatory Bowel Disease. <i>Annals of Internal Medicine</i> , 2022, 175, 1374-1382.	2.0	11
84	The Trajectory of the COVID-19 Vaccine Antibody Titers Over Time and the Association of Mycophenolate Mofetil in Solid Organ Transplant Recipients. <i>Transplantation Proceedings</i> , 2022, 54, 2638-2645.	0.3	1
86	A combination vaccine against SARS-CoV-2 and H1N1 influenza based on receptor binding domain trimerized by six-helix bundle fusion core. <i>EBioMedicine</i> , 2022, 85, 104297.	2.7	11
87	Hospital trajectories and early predictors of clinical outcomes differ between SARS-CoV-2 and influenza pneumonia. <i>EBioMedicine</i> , 2022, 85, 104295.	2.7	5
88	Association of COVID-19 Vaccinations With Intensive Care Unit Admissions and Outcome of Critically Ill Patients With COVID-19 Pneumonia in Lombardy, Italy. <i>JAMA Network Open</i> , 2022, 5, e2238871.	2.8	19
89	Type of mRNA COVID-19 vaccine and immunomodulatory treatment influence humoral immunogenicity in patients with inflammatory rheumatic diseases. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	8
90	Factors associated with COVID-19 breakthrough infection among vaccinated patients with rheumatic diseases: A cohort study. <i>Seminars in Arthritis and Rheumatism</i> , 2023, 58, 152108.	1.6	23
91	Effectiveness of mRNA COVID-19 Vaccine Boosters Against Infection, Hospitalization, and Death: A Target Trial Emulation in the Omicron (B.1.1.529) Variant Era. <i>Annals of Internal Medicine</i> , 2022, 175, 1693-1706.	2.0	25
92	Fully understanding the efficacy profile of the COVID-19 vaccination and its associated factors in multiple real-world settings. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	5

#	ARTICLE	IF	CITATIONS
93	First Scientific Evidence about the Estimation of the Odds Ratio in Vaccinated Individuals and Determination of Vaccine Efficacy against SARS-CoV-2 Infection in Angola”Part I. Covid, 2022, 2, 1477-1490.	0.7	0
94	Comparison of Maternal and Neonatal Antibody Levels After COVID-19 Vaccination vs SARS-CoV-2 Infection. JAMA Network Open, 2022, 5, e2240993.	2.8	14
95	Vertigo/dizziness following COVID-19 vaccination. American Journal of Otolaryngology - Head and Neck Medicine and Surgery, 2023, 44, 103723.	0.6	4
96	Diabetes Affects Antibody Response to SARS-CoV-2 Vaccination in Older Residents of Long-term Care Facilities: Data From the GeroCovid Vax Study. Diabetes Care, 2022, 45, 2935-2942.	4.3	11
97	IgG anti-RBD levels during 8-month follow-up post-vaccination with BNT162b2 and mRNA-1273 vaccines in healthcare workers: A one-center study. Frontiers in Cellular and Infection Microbiology, 0, 12, .	1.8	7
98	Impact of vaccination on postacute sequelae of SARS CoV-2 infection in patients with rheumatic diseases. Annals of the Rheumatic Diseases, 2023, 82, 565-573.	0.5	8
99	Impact of immunosuppressive treatment and type of SARS-CoV-2 vaccine on antibody levels after three vaccinations in patients with chronic kidney disease or kidney replacement therapy. CKJ: Clinical Kidney Journal, 2023, 16, 528-540.	1.4	8
100	Use of Whole-Genome Sequencing to Estimate the Contribution of Immune Evasion and Waning Immunity on Decreasing COVID-19 Vaccine Effectiveness. Journal of Infectious Diseases, 0, , .	1.9	2
102	Effectiveness of Covid-19 vaccines against symptomatic and asymptomatic SARS-CoV-2 infections in an urgent care setting. Vaccine, 2023, 41, 989-998.	1.7	1
103	Comparative Effectiveness of BNT162b2 and mRNA-1273 Vaccines Against COVID-19 Infection Among Patients With Systemic Autoimmune Rheumatic Diseases on Immunomodulatory Medications. Journal of Rheumatology, 2023, 50, 697-703.	1.0	4
105	Emulating a target trial using primary care electronic health records: SGLT-2i medications and Hemoglobin A1c. American Journal of Epidemiology, 0, , .	1.6	0
106	Waning of humoral immunity depending on the types of COVID-19 vaccine. Infectious Diseases, 2023, 55, 216-220.	1.4	5
107	Predictive Value of Reactogenicity for Anti-SARS-CoV-2 Antibody Response in mRNA-1273 Recipients: A Multicenter Prospective Cohort Study. Vaccines, 2023, 11, 120.	2.1	4
108	Evaluation of a point of care lateral flow assay for antibody detection following SARS CoV-2 mRNA vaccine series. Journal of Immunological Methods, 2023, 513, 113410.	0.6	1
109	Comparative effectiveness of third doses of mRNA-based COVID-19 vaccines in US veterans. Nature Microbiology, 2023, 8, 55-63.	5.9	16
110	COVID-19 Vaccine Effectiveness Against the Omicron Variant in a Veterans Affairs Cohort of Patients With Inflammatory Bowel Disease. American Journal of Gastroenterology, 2023, 118, 664-673.	0.2	3
111	Symptoms of Long-COVID 1-Year after a COVID-19 outbreak among sailors on a French aircraft carrier. Infectious Diseases Now, 2023, 53, 104673.	0.7	0
112	Efficacy and safety of booster vaccination against SARS-CoV-2 in dialysis and renal transplant patients: systematic review and meta-analysis. International Urology and Nephrology, 2023, 55, 791-802.	0.6	2

#	ARTICLE	IF	CITATIONS
113	Frailty Reduces Vaccine Effectiveness Against SARS-CoV-2 Infection: A Test-Negative Case Control Study Using National VA Data. <i>Journal of Nutrition, Health and Aging</i> , 2023, 27, 81-88.	1.5	4
114	A comprehensive evaluation of humoral immune response to second and third SARS-CoV-2 mRNA vaccination in patients with malignant lymphoma. <i>International Journal of Hematology</i> , 2023, 117, 900-909.	0.7	1
115	Variants of SARS-CoV-2: Influences on the Vaccinesâ€™ Effectiveness and Possible Strategies to Overcome Their Consequences. <i>Medicina (Lithuania)</i> , 2023, 59, 507.	0.8	5
116	Target Trial Emulation Using Hospital-Based Observational Data: Demonstration and Application in COVID-19. <i>Life</i> , 2023, 13, 777.	1.1	2
117	Comparative effectiveness of BNT162b2 versus mRNA-1273 covid-19 vaccine boosting in England: matched cohort study in OpenSAFELY-TPP. <i>BMJ, The</i> , 0, , e072808.	3.0	17
118	Humoral and cellular immunity to SARS-COV-2 after vaccination with mRNA vaccines in PLWH with discordant immune response. Influence of the vaccine administered. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	6
130	Therapeutic Interventions for COVID-19. , 0, , .		0
144	mRNA vaccines in disease prevention and treatment. <i>Signal Transduction and Targeted Therapy</i> , 2023, 8, .	7.1	9